A review of FDA reports between 2017 and 2024 revealed a link between certain obesity and diabetes medications, such as Wegovy and Ozempic, and rare cases of ischemic optic neuropathy, also known as ocular stroke, which can lead to sudden and permanent vision loss.
Data indicated that Wegovy, approved in 2021, carries roughly a fivefold higher risk of optic nerve injury compared to Ozempic, with men reporting complications three times more often than women.
No similar association was observed with Terzepatide or the slow-absorbing oral version, Rybelsus, which reduces peak blood concentrations.
Dr. Edward Margolin, ophthalmology professor at the University of Toronto, emphasized that these cases are very rare, and most patients should not expect severe complications, but careful monitoring of doses and the speed of weight loss is crucial. Rapid and significant weight loss may strain the body, increasing the likelihood of complications with high doses of Wegovy or Ozempic.
Studies indicate that ischemic optic neuropathy can cause permanent optic nerve damage if blood flow is not restored promptly, although such cases remain rare, particularly in individuals under 50.
For more details and the latest news, follow Misr Connect
